Zhi Tong Cai Jing·2026-01-05 09:01Core Viewpoint - The company, CanSino Biologics (06185), has received approval from the National Medical Products Administration of China to conduct clinical trials for its 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) [1] Group 1: Product Development - The PCV24 vaccine covers the major circulating serotypes of pneumococcus and utilizes a covalent binding method of polysaccharide antigens with protein carriers, along with a dual carrier technology [1] - The vaccine is intended for administration to individuals aged 2 months (minimum 6 weeks) and older to prevent infectious diseases caused by 24 serotypes of pneumococcus [1] - The product has completed the development and confirmation of the production process for purified polysaccharides from 24 serotypes, polysaccharide-protein conjugate bulk, and the final formulation [1] Group 2: Market Context - As of the date of this announcement, there are no marketed products for the 24-valent pneumococcal polysaccharide conjugate vaccine both domestically and internationally [1]